Abstract
The idea that within the bulk of leukemic cells there are immature progenitors which are intrinsically resistant to chemotherapy and able to repopulate the tumor after treatment is not recent. Nevertheless, the term leukemia stem cells (LSCs) has been adopted recently to describe these immature progenitors based on the fact that they share the most relevant features of the normal hematopoetic stem cells (HSCs), i.e. the self-renewal potential and quiescent status. LSCs differ from their normal counterparts and from the more differentiated leukemic cells regarding the default status of pathways regulating apoptosis, cell cycle, telomere maintenance and transport pumps activity. In addition, unique features regarding the interaction of these cells with the microenvironment have been characterized. Therapeutic strategies targeting these unique features are at different stages of development but the reported results are promising. The aim of this review is, by taking acute myeloid leukemia (AML) as a bona fide example, to discuss some of the mechanisms used by the LSCs to survive and the strategies which could be used to eradicate these cells.
Keywords: Leukemia stem cells, acute myeloid leukemia, bone marrow microenvironment
Anti-Cancer Agents in Medicinal Chemistry
Title: Targeting the Acute Myeloid Leukemia Stem Cells
Volume: 10 Issue: 2
Author(s): Alexandre Krause, Luciana M. Fontanari Krause and Eduardo M. Rego
Affiliation:
Keywords: Leukemia stem cells, acute myeloid leukemia, bone marrow microenvironment
Abstract: The idea that within the bulk of leukemic cells there are immature progenitors which are intrinsically resistant to chemotherapy and able to repopulate the tumor after treatment is not recent. Nevertheless, the term leukemia stem cells (LSCs) has been adopted recently to describe these immature progenitors based on the fact that they share the most relevant features of the normal hematopoetic stem cells (HSCs), i.e. the self-renewal potential and quiescent status. LSCs differ from their normal counterparts and from the more differentiated leukemic cells regarding the default status of pathways regulating apoptosis, cell cycle, telomere maintenance and transport pumps activity. In addition, unique features regarding the interaction of these cells with the microenvironment have been characterized. Therapeutic strategies targeting these unique features are at different stages of development but the reported results are promising. The aim of this review is, by taking acute myeloid leukemia (AML) as a bona fide example, to discuss some of the mechanisms used by the LSCs to survive and the strategies which could be used to eradicate these cells.
Export Options
About this article
Cite this article as:
Krause Alexandre, Fontanari Krause M. Luciana and Rego M. Eduardo, Targeting the Acute Myeloid Leukemia Stem Cells, Anti-Cancer Agents in Medicinal Chemistry 2010; 10 (2) . https://dx.doi.org/10.2174/187152010790909281
DOI https://dx.doi.org/10.2174/187152010790909281 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Transcriptomic Effects of Estrogen Starvation and Induction in the MCF7 Cells. The Meta-analysis of Microarray Results
Current Pharmaceutical Biotechnology Cyclin-Dependent Kinase Inhibitors as Anticancer Drugs
Current Drug Targets Inflammation and Anemia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Differential Involvement of Myosin II and VI in the Spontaneous and SDF- 1-induced Migration of Adult CD133+ Hematopoietic Stem/Progenitor Cells and Leukemic Cells
Current Cancer Therapy Reviews Biological and Clinical Significance of Polymorphisms in NAD(P)H: Quinone Oxidoreductase 1 (NQO1)
Current Pharmacogenomics Metabolomics: A Revolution for Novel Cancer Marker Identification
Combinatorial Chemistry & High Throughput Screening Update on Myositis Therapy: From Today’s Standards to Tomorrow’s Possibilities
Current Pharmaceutical Design ROCK Inhibitors as Emerging Therapeutic Candidates for Sarcomas
Current Cancer Drug Targets Targeting Stem Cells-Clinical Implications for Cancer Therapy
Current Stem Cell Research & Therapy Role of Cytokines in Regulating Feeding Behaviour
Current Drug Targets Histone Deacetylase Inhibitors: A Review on Class-I Specific Inhibition
Mini-Reviews in Medicinal Chemistry Myelodysplastic Syndromes: Review of Pathophysiology and Current Novel Treatment Approaches
Current Cancer Drug Targets From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis
Current Neuropharmacology Interplay between Epigenetics & Cancer Metabolism
Current Pharmaceutical Design The Genetic Basis of New Treatment Modalities in Melanoma
Current Drug Targets Ricin and Saporin: Plant Enzymes for the Research and the Clinics
Current Chemical Biology Alkaloids from Cyanobacteria with Diverse Powerful Bioactivities
Mini-Reviews in Medicinal Chemistry Refractory Chronic Lymphocytic Leukemia: A Therapeutic Challenge
Current Cancer Drug Targets Direct Modification of Bioactive Phenothiazines by Exposure to Laser Radiation
Recent Patents on Anti-Infective Drug Discovery CYP1A1 and CYP2D6 Polymorphisms and Susceptibility to Chronic Myelocytic Leukaemia
Current Cancer Drug Targets